Overview
Ticagrelor is a medication that is used to prevent blood clots in people with acute coronary syndrome, a condition that can lead to heart attacks or strokes. It is sold under the brand name Brilinta and is classified as a platelet aggregation inhibitor.
The ticagrelor market has been steadily growing over the years due to the increasing incidence of acute coronary syndrome and the growing awareness about the benefits of antiplatelet drugs in preventing blood clots. The market growth can be attributed to several factors such as the increasing prevalence of cardiovascular diseases, growing geriatric population, and rising demand for personalized medicine. Additionally, the launch of new formulations, increasing R&D activities, and favourable reimbursement policies are also expected to drive the market growth in the coming years.
North America is currently the largest market for ticagrelor, followed by Europe and Asia-Pacific. The dominance of these regions can be attributed to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and increasing awareness about the benefits of antiplatelet drugs.
Some of the key players operating in the ticagrelor market include AstraZeneca, Hunan Warrant Pharmaceutical Co., Ltd., Zydus Cadila, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd., among others. These players are actively involved in R&D activities to develop new formulations and expand their product portfolio to cater to the growing demand for ticagrelor.
Segment Overview
The ticagrelor market can be segmented based on various factors such as application, dosage form, distribution channel, and region.
1. Application: Ticagrelor is primarily used in the prevention of thrombotic events in patients with acute coronary syndrome. It can also be used in patients with a history of heart attack or stroke. Therefore, the market can be segmented based on its application in the treatment of acute coronary syndrome and other cardiovascular diseases.
2. Dosage Form: Ticagrelor is available in oral tablets and injectable formulations. The oral tablets are the most commonly prescribed dosage form. The market can be segmented based on the dosage form, with the oral tablets segment being the largest.
3. Distribution Channel: Ticagrelor is sold through various distribution channels such as hospitals, pharmacies, and online channels. The hospital segment is the largest, as ticagrelor is primarily used in hospitals for the treatment of acute coronary syndrome.
4. Region: The ticagrelor market can be segmented based on the region, with North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa being the major regions. North America is currently the largest market for ticagrelor, followed by Europe and Asia-Pacific.
Overall, the ticagrelor market is expected to witness significant growth in the coming years due to the increasing prevalence of cardiovascular diseases and the growing awareness about the benefits of antiplatelet drugs. The market segmentation will help the manufacturers and marketers to better understand the market trends and develop targeted marketing strategies to reach their customers.
Geographical Overview
The ticagrelor market is a global market, with North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa being the major regions.
1. North America: North America is currently the largest market for ticagrelor. The high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and increasing awareness about the benefits of antiplatelet drugs are some of the factors driving the market growth in this region.
2. Europe: Europe is the second-largest market for ticagrelor. The growing geriatric population and increasing incidence of cardiovascular diseases are some of the factors contributing to the market growth in this region.
3. Asia-Pacific: The Asia-Pacific region is expected to witness significant growth in the ticagrelor market in the coming years. The increasing healthcare expenditure, growing awareness about cardiovascular diseases, and rising demand for personalized medicine are some of the factors driving the market growth in this region.
4. Latin America: The ticagrelor market in Latin America is expected to grow at a significant rate due to the increasing incidence of cardiovascular diseases and growing demand for antiplatelet drugs.
5. Middle East & Africa: The ticagrelor market in the Middle East & Africa region is also expected to witness significant growth in the coming years due to the increasing healthcare expenditure, growing awareness about cardiovascular diseases, and rising demand for antiplatelet drugs.
Overall, the ticagrelor market is expected to witness significant growth across all regions, with North America and Europe being the major markets due to the high prevalence of cardiovascular diseases and well-established healthcare infrastructure. However, the Asia-Pacific region is expected to witness the fastest growth in the coming years due to the increasing healthcare expenditure and rising demand for personalized medicine.
COVID Impact
The COVID-19 pandemic has had a mixed impact on the ticagrelor market. While the pandemic has led to disruptions in the supply chain and reduced patient visits to hospitals and clinics, it has also led to increased awareness about the importance of preventing and managing cardiovascular diseases, which has led to an increased demand for antiplatelet drugs such as ticagrelor.
The pandemic has had a significant impact on the supply chain of ticagrelor, with disruptions in the manufacturing and distribution of the drug. However, the pharmaceutical industry has responded by ramping up production and finding alternative supply sources to ensure the availability of the drug.
The pandemic has also led to a reduction in patient visits to hospitals and clinics for non-COVID related health issues, including cardiovascular diseases. This has led to a reduction in the number of patients being diagnosed with acute coronary syndrome and a reduction in the demand for ticagrelor.
However, the pandemic has also led to an increased awareness about the importance of managing cardiovascular diseases, as patients with pre-existing cardiovascular conditions are at a higher risk of developing severe COVID-19. This has led to an increased demand for antiplatelet drugs such as ticagrelor, as they are an important component of the management of cardiovascular diseases.
Overall, the impact of the COVID-19 pandemic on the ticagrelor market has been mixed, with disruptions in the supply chain and reduced patient visits to hospitals and clinics leading to a reduction in demand, but increased awareness about the importance of managing cardiovascular diseases leading to an increased demand for antiplatelet drugs such as ticagrelor.
Competitive Analysis
The ticagrelor market is highly competitive, with several major players operating in the market. Some of the key players in the market include:
1. AstraZeneca: AstraZeneca is the manufacturer of Brilinta, the brand name for ticagrelor. It is one of the leading players in the market, with a strong presence in North America, Europe, and Asia-Pacific.
2. Pfizer Inc.: Pfizer is another major player in the ticagrelor market, with its antiplatelet drug, Effient (prasugrel), which is used in the treatment of acute coronary syndrome.
3. Sanofi S.A.: Sanofi is a leading player in the antiplatelet market, with its drug Plavix (clopidogrel) being one of the most widely used antiplatelet drugs in the world. Sanofi also manufactures Ticlopidine, which is another antiplatelet drug used in the treatment of cardiovascular diseases.
4. Johnson & Johnson: Johnson & Johnson is another major player in the ticagrelor market, with its antiplatelet drug, Xarelto (rivaroxaban), which is used in the treatment of deep vein thrombosis and pulmonary embolism.
5. Eli Lilly and Company: Eli Lilly is a major player in the cardiovascular drug market, with its drug Effient (prasugrel), which is used in the treatment of acute coronary syndrome.
Other players in the market include Bristol-Myers Squibb, Daiichi Sankyo, and Boehringer Ingelheim. The key strategies adopted by these players in the market include new product launches, partnerships, mergers and acquisitions, and geographic expansion.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
Only Three Thousand Nine Hundred Fifty US dollar
Only Four Thousand Nine Hundred Fifty US dollar
Only Five Thousand Nine Hundred Fifty US dollar